论文部分内容阅读
目的探讨FOLFOX4方案治疗中晚期胃癌的近期疗效及不良反应。方法将60例中晚期胃癌患者随机分为观察组(30例)和对照组(30例),观察组采用FOLFOX4方案治疗,对照组采用EPLF方案治疗,比较两组患者的近期疗效和不良反应。结果观察组的近期总有效率为53.3%,与对照组的46.7%相比,差异无统计学意义(P>0.05)。观察组生活质量改善率为63.3%,显著高于对照组36.7%(P<0.05),不良反应发生率显著低于对照组(P<0.05)。结论 FOLFOX方案和EPLF方案治疗中晚期胃癌近期疗效相当,但FOLFOX方案对机体损伤更加轻微,毒副作用小,患者易于接受。
Objective To investigate the short-term efficacy and side effects of FOLFOX4 regimen in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer were randomly divided into observation group (30 cases) and control group (30 cases). The observation group was treated with FOLFOX4 regimen. The control group was treated with EPLF regimen. The short-term curative effect and adverse reactions were compared between the two groups. Results The total effective rate in the observation group was 53.3%. Compared with 46.7% in the control group, the difference was not statistically significant (P> 0.05). The improvement rate of quality of life in the observation group was 63.3%, significantly higher than that in the control group (36.7%, P <0.05), and the incidence of adverse reactions was significantly lower than that in the control group (P <0.05). Conclusion FOLFOX regimen and EPLF regimen have similar efficacy in the treatment of advanced gastric cancer. However, the FOLFOX regimen is less harmful to the body and has fewer side effects and is easy for patients to accept.